The abstract is read at the publisher; the summary is JClub's.
Multimodal obesity care should extend beyond GLP-1 pharmacotherapy to include screening, early management, and intensive behavioral therapy across the life course.
- Why it matters: Current obesity management risks being overly medication-centered, leaving gaps in early identification and sustained behavioral support for comorbidities.
- What they did: The perspective synthesizes an approach that pairs GLP-1 therapy with ongoing screening and staged behavioral interventions throughout patients’ lives.
- The result: It supports a care model that may improve outcomes by coordinating medical and behavioral strategies rather than relying on drugs alone.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.